Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 4 105 M
EBIT 2016 999 M
Net income 2016 556 M
Debt 2016 3 537 M
Yield 2016 1,89%
Sales 2017 4 301 M
EBIT 2017 1 048 M
Net income 2017 623 M
Debt 2017 3 343 M
Yield 2017 2,03%
P/E ratio 2016 21,96
P/E ratio 2017 19,78
EV / Sales2016 3,62x
EV / Sales2017 3,41x
Capitalization 11 323 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
11/22 GLOBAL PLASMA FRACTIONATION MARKET 2 : Baxter, CSL, Grifols, Octapharma, BPL
11/17 Aradigm Announces Third Quarter 2016 Financial Results
11/10 ARADIGM CORPORATION (NASDAQ : ARDM) Files An 8-K Announces Third Quarter 2016 Fi..
11/03 GRIFOLS : Author of Blue Blue Sea Finds His Cape Donates to Immune Deficiency Fo..
10/21 GRIFOLS : The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Bot..
10/13 GRIFOLS : relocates its headquarters in Germany to a new office building
09/29 GLOBAL FIBRIN SEALANT (HUMAN) MARKET : Baxter, CSL, Bayer, Grifols, Octapharma, ..
09/27 GRIFOLS : Author of "Blue Blue Sea Finds His Cape" to Donate to Immune Deficienc..
09/07 NOVO NORDISK A/S : Johnston County's 2015 was like none other
09/05 GRIFOLS : Opens Diagnostic Training Center in Dubai
More news
Sector news : Biopharmaceuticals
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Biopharmaceuticals
News from SeekingAlpha
01/04 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 21,4 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Víctor Grifols Roura Chairman, President & Chief Executive Officer
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Eva Bastida Tubau VP, Director-Scientific & Medical Affairs
Vicente Blanquer Torre Vice President-Quality, Research & Development
Ramón Riera Roca Executive Director, VP-Marketing & Sales
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA0.00%12 072
BIOGEN INC-3.45%64 661
CSL LIMITED-5.78%33 156
ALEXION PHARMACEUTICAL..-35.54%27 574
BIOMARIN PHARMACEUTICA..-18.26%14 139
GRIFOLS SA-15.08%12 072
More Results